Screener
ImmunityBio, Inc. IBRX Equity Method Income
Discontinued — last reported Q4 '25
Equity Method Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromEquityMethodInvestments.
The source filing: ImmunityBio, Inc.’s 10-K, filed February 23, 2026.
- Filed
- Feb 23, 2026, 5:24 PM EST
- Fiscal year
- FY2025
- Accession
- 0001326110-26-000030
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 | Year Ended December 31, 2023 |
|---|---|---|---|
| Change in fair value of related-party convertible note | (42,773) | 43,472 | (36,203) |
| Change in fair value of derivative liabilities | 6,398 | 13,477 | — |
| Interest expense | (99) | (82) | (86) |
| Loss on equity method investment | — | — | (7,549) |
| Other expense, net | (2,174) | (15) | (2,223) |
| Total other expense, net | (95,580) | (69,463) | (221,642) |
| Loss before income taxes and noncontrolling interests | (351,607) | (413,645) | (583,892) |
| Income tax benefit | 135 | — | 40 |
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.
FAQ
- What is ImmunityBio, Inc.'s equity method income?
- ImmunityBio, Inc. (IBRX) reported equity method income of $0 in Q4 2025.
- What is the long-term trend for ImmunityBio, Inc.'s equity method income?
- Over 4 years (2021 to 2025), ImmunityBio, Inc.'s equity method income has grown at a -100.0% compound annual growth rate (CAGR), from -$803K to $0.
- What does equity method income mean?
- The company's proportional share of net income or loss from unconsolidated affiliates and joint ventures accounted for under the equity method.
Ask your AI about ImmunityBio, Inc.'s equity method income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude